ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages GoodRx Holdings, Inc. Buyers with Losses Exceeding $100Okay to Safe Counsel Earlier than Necessary February 16 Deadline – GDRX

NEW YORK, February 5, 2021 (GLOBE NEWSWIRE) – WHY: Rosen Law Firm, a global investor rights law firm, will remind buyers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020 (including the “Class Period”) February 16, 2021 lead plaintiff deadline.

SO WHAT: If you purchased GoodRx securities during the class period, you may be entitled to compensation without paying any out-of-pocket expenses or cost through a contingent fee agreement.

WHAT TO DO NEXT: To participate in the GoodRx class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or email or for information about the class action. A class action lawsuit has already been filed. If you want to stand as the lead plaintiff, you must move the court no later than February 16, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in directing the dispute.

WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record in leadership roles. Companies that issue notices often lack comparable experience or resources. Rosen law firm represents investors around the world and focuses on class action and securities disputes. The Rosen law firm has filed the largest class action lawsuit against a Chinese company to date. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for number of class action settlements in 2017. The law firm has been in the top 3 every year since 2013 and has collected hundreds of millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was named the Titan of Plaintiffs’ Bar by Act 360. Many of the firm’s attorneys are recognized by Lawdragon and Super Lawyers.

The story goes on

DETAILS OF THE CASE: GoodRx’s class action lawsuit alleges that, Inc. was developing, and is about to launch, its own online and mobile prescription drug order and fulfillment service without the knowledge of investors at the time the company went public (“IPO”) would compete directly with GoodRx. Defendants planned the IPO so that the price was set before Amazon announced its online pharmaceutical business in order to facilitate the IPO and create an artificial demand for the common stock sold in it, as well as to maximize the amount of money the company and the Selling shareholders could raise in the IPO. According to GoodRx’s class action suit, their statements in the registration statement and during the class period about GoodRx’s competitive position were materially false and / or misleading with respect to GoodRx’s competitive position, given the knowledge of the defendants’ intentions to enter the online pharmaceutical business, as they made the GoodRx class and created a common stock to trade at artificially inflated prices of more than $ 64 per share during the class period.

On November 17, 2020, just weeks after GoodRx went public, Amazon announced two new pharmacy offerings, a Prime Rx plan and a discount card program that would, among other things, directly compete with the GoodRx platform by being “easy for” Customers can compare prices and purchase medicines for home delivery in one place. “In response to this news, GoodRx Class A common stock fell 23% from $ 46.72 per share to $ 36.21 per share, depending on the market close on November 17, 2020, hurting investors.

To participate in the GoodRx class action lawsuit, go to or call Phillip Kim, Esq. toll free at 866-767-3653 or email or for information about the class action.

No class has yet been certified for the above promotion. Until a class is certified, you will not be represented by an attorney unless you keep one. You can keep an attorney of your choice. You can also remain an absent class member and do nothing at this point. An investor’s ability to participate in a possible future recovery does not depend on whether they are the lead plaintiff.

Follow us for updates on LinkedIn:, on Twitter: or on Facebook: https: // www. facebook .com / rosenlawfirm /.

Lawyer advertising. Previous results do not guarantee a similar result.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen, PA law firm
275 Madison Avenue, 40th floor
New York, NY 10016
Tel .: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827

Leave a Comment